Radiodermatitis Market by Product (Topical, Oral Drugs, and Dressings) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2019-2027
- Published Date: 2020-11-26
- Report ID: 21708
- Pages: 213
-
Format:
The global radiodermatitis market was valued at $477.48 million in 2019, and is projected to reach $609.68 million by 2027, registering a CAGR of 4.1% from 2020 to 2027.
Radiodermatitis is a cutaneous reaction that occurs as one of the side effects of radiotherapy during cancer treatment or sometimes after interventional radiology. It is one of the most common side effects of radiation therapies used in carcinoma mostly for breasts, head & neck tumors, lungs, and soft tissue sarcomas. According to an article published in the American Journal of Clinical Dermatology in 2016, it is estimated that 95% of cancer patients receiving radiation therapy would develop some form of radiodermatitis, including erythema, dry desquamation, and moist desquamation. Radiodermatitis can further be classified as acute and chronic. Acute radiation dermatitis occurs within 90 days of exposure to radiation.
Chronic radiodermatitis is an extension of acute process and involves further inflammatory changes in skin. The onset of chronic radiation dermatitis may occur from 15 days to 10 years or more after the beginning of a radiation therapy and can be characterized by:
Disappearance of follicular structures
Increase in collagen and damage to elastic fibers in the dermis
Fragile surface skin (epidermis)
Telangiectasia (prominent blood vessels).
Growth of the global radiodermatitis market is majorly driven by increase in prevalence of cancer and rise in adoption of radiotherapy for treatment globally. Furthermore, increase in geriatric population also fuels growth of the radiodermatitis market. However, high cost associated with radiodermatitis treatment is anticipated to restrict growth of the market. On the contrary, increase in demand for reduction of side effects associated with radiation therapy is expected to offer lucrative opportunities for the market expansion during the forecast period.
The global radiodermatitis market is segmented into product, distribution channel, and region. On the basis of product, the market is fragmented into topical, oral drugs, and dressings. The topical products segment is further divided into corticosteroids, hydrophilic creams, topical antibiotics, and others. The dressings segment is divided into hydrogel and hydrocolloid dressings, no sting barrier film, honey impregnated gauze, silicone coated, and others. By distribution channel, it is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis of the current market trends from 2019 to 2027 to identify prevailing opportunities along with strategic assessment of the global radiodermatitis market.
Market size and estimations are based on a comprehensive analysis of end users, developments, and services in the industry.
An in-depth analysis based on region assists to understand the regional market and facilitates strategic business planning.
Developmental strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Product
Topical
o Corticosteroids
o Hydrophilic Creams
o Topical Antibiotics
o Others
Oral Drugs
Dressings
o Hydrogel and Hydrocolloid Dressings
o No Sting Barrier Film
o Honey Impregnated Gauze
o Silicone Coated
o Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Australia
o Japan
o India
o China
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
KEY MARKET PLAYERS
3M COMPANY
BAUSCH HEALTH COMPANIES INC
BAYER AG
BMG PHARMA SPA
CONVATEC GROUP PLC
GLAXOSMITHKLINE PLC
HELSINN HEALTHCARE SA
MOLNLYCKE HEALTH CARE
MYLAN N.V.
SMITH & NEPHEW PLC
STRATPHARMA AG
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.1.Top winning strategies
3.4.Top player positioning, 2019
3.5.Porters five forces analysis
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Growth in the geriatric population
3.6.1.2.Increase in prevalence of cancer
3.6.1.3.Rise in the adoption of radiotherapy
3.6.2.Restraints
3.6.2.1.Higher radiodermatitis cost
3.6.3.Opportunity
3.6.3.1.Increase in demand for reduction of side effects associated with radiation therapy
3.7.COVID-19 impact analysis for radiodermatitis market
3.8.Reimbursement scenario
3.9.Approved radiodermatitis products with prices
3.10.Pipeline analysis
CHAPTER 4:GLOBAL RADIODERMATITIS MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Topical
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Corticosteroids
4.2.2.1.1.Market size and forecast
4.2.2.2.Hydrophilic creams
4.2.2.2.1.Market size and forecast
4.2.2.3.Topical antibiotics
4.2.2.3.1.Market size and forecast
4.2.2.4.Others
4.2.2.4.1.Market size and forecast
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Oral drugs
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Dressings
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type
4.4.2.1.Hydrogel and hydrocolloid dressings
4.4.2.1.1.Market size and forecast
4.4.2.2.No sting barrier film
4.4.2.2.1.Market size and forecast
4.4.2.3.Honey impregnated gauze
4.4.2.3.1.Market size and forecast
4.4.2.4.Silicone coated
4.4.2.4.1.Market size and forecast
4.4.2.5.Others
4.4.2.5.1.Market size and forecast
4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country
CHAPTER 5:RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospital pharmacy
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Retail pharmacy
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Online pharmacy
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
CHAPTER 6:GLOBAL RADIODERMATITIS MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends and opportunities
6.2.2.Market size and forecast, by country
6.2.2.1.U.S. radiodermatitis market, by product
6.2.2.2.U.S. radiodermatitis market, by distribution channel
6.2.2.3.Canada radiodermatitis market, by product
6.2.2.4.Canada radiodermatitis market, by distribution channel
6.2.2.5.Mexico radiodermatitis market, by product
6.2.2.6.Mexico radiodermatitis market, by distribution channel
6.2.3.North America radiodermatitis market, by product
6.2.4.North America Radiodermatitis Market, by distribution channel
6.3.Europe
6.3.1.Key market trends and opportunities
6.3.2.Market size and forecast, by country
6.3.2.1.Germany radiodermatitis market, by product
6.3.2.2.Germany radiodermatitis market, by distribution channel
6.3.2.3.France radiodermatitis market, by product
6.3.2.4.France radiodermatitis market, by distribution channel
6.3.2.5.UK radiodermatitis market, by product
6.3.2.6.UK radiodermatitis market, by distribution channel
6.3.2.7.Italy radiodermatitis market, by product
6.3.2.8.Italy radiodermatitis market, by distribution channel
6.3.2.9.Spain radiodermatitis market, by product
6.3.2.10.Spain radiodermatitis market, by distribution channel
6.3.2.11.Rest of Europe radiodermatitis market, by product
6.3.2.12.Rest of Europe radiodermatitis market, by distribution channel
6.3.3.Europe radiodermatitis market, by product
6.3.4.Europe radiodermatitis market, by distribution channel
6.4.Asia-Pacific
6.4.1.Key market trends and opportunities
6.4.2.Market size and forecast, by country
6.4.2.1.Japan radiodermatitis market, by product
6.4.2.2.Japan radiodermatitis market, by distribution channel
6.4.2.3.China radiodermatitis market, by product
6.4.2.4.China radiodermatitis market, by distribution channel
6.4.2.5.India radiodermatitis market, by product
6.4.2.6.India radiodermatitis market, by distribution channel
6.4.2.7.Australia radiodermatitis market, by product
6.4.2.8.Australia radiodermatitis market, by distribution channel
6.4.2.9.South Korea radiodermatitis market, by product
6.4.2.10.South Korea radiodermatitis market, by distribution channel
6.4.2.11.Rest of Asia-Pacific radiodermatitis market, by product
6.4.2.12.Rest of Asia-Pacific radiodermatitis market, by distribution channel
6.4.3.Asia-Pacific radiodermatitis market, by product
6.4.4.Asia-Pacific radiodermatitis market, by distribution channel
6.5.LAMEA
6.5.1.Key market trends and opportunities
6.5.2.Market size and forecast, by country
6.5.2.1.Brazil radiodermatitis market, by product
6.5.2.2.Brazil radiodermatitis market, by distribution channel
6.5.2.3.Saudi Arabia radiodermatitis market, by product
6.5.2.4.Saudi Arabia radiodermatitis market, by distribution channel
6.5.2.5.South Africa radiodermatitis market, by product
6.5.2.6.South Africa radiodermatitis market, by distribution channel
6.5.2.7.Rest of LAMEA radiodermatitis market, by product
6.5.2.8.Rest of LAMEA radiodermatitis market, by distribution channel
6.5.3.LAMEA radiodermatitis market, by product
6.5.4.LAMEA radiodermatitis market, by distribution channel
CHAPTER 7:COMPANY PROFILES
7.1.THE 3M COMPANY
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.BAYER AG.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.3.BAUSCH HEALTH COMPANIES INC.
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.BMG PHARMA S.P.A.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.5.CONVATEC GROUP PLC.
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.GLAXOSMITHKLINE PLC
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance.
7.7.HELSINN HEALTHCARE SA
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Key strategic moves and developments
7.8.MOLNLYCKE HEALTH CARE AB
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.MYLAN N.V.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.STRATPHARMA AG
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and developments
7.11.SMITH & NEPHEW PLC
7.11.1.Company overview
7.11.2.Company snapshot
7.11.3.Operating business segments
7.11.4.Product portfolio
7.11.5.Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
